MOG has been approved by the Food and Drug Administration (FDA) for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Here, MOG is linked to primary cutaneous T-cell non-Hodgkin lymphoma.